<?xml version="1.0" encoding="UTF-8"?>
<p id="p0110">With the identification of the ACE-2r receptor as the binding site for SARS-CoV-2 spike protein and its corresponding tropism, there was a groundswell of concern that ACE inhibitors and/or angiotensin receptor blockers would confer an increased risk upon infected patients. However, patients with COVID-19, who were treated with ACE-inhibitors or angiotensin receptor blockers, continue to derive both cardiovascular and renal protection, and in fact, the discontinuation of these agents may in fact be harmful [
 <xref rid="bb0190" ref-type="bibr">38</xref>].
</p>
